DE1442162A1 - Verfahren zur Gewinnung von Urokinase - Google Patents
Verfahren zur Gewinnung von UrokinaseInfo
- Publication number
- DE1442162A1 DE1442162A1 DE19651442162 DE1442162A DE1442162A1 DE 1442162 A1 DE1442162 A1 DE 1442162A1 DE 19651442162 DE19651442162 DE 19651442162 DE 1442162 A DE1442162 A DE 1442162A DE 1442162 A1 DE1442162 A1 DE 1442162A1
- Authority
- DE
- Germany
- Prior art keywords
- urokinase
- urine
- precipitate
- solution
- eluted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 title claims description 124
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 title claims description 124
- 229960005356 urokinase Drugs 0.000 title claims description 124
- 238000000034 method Methods 0.000 title claims description 42
- 230000008569 process Effects 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 210000002700 urine Anatomy 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000002244 precipitate Substances 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 239000000440 bentonite Substances 0.000 claims description 9
- 229910000278 bentonite Inorganic materials 0.000 claims description 9
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical class [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001698 pyrogenic effect Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 description 27
- 239000007788 liquid Substances 0.000 description 15
- 238000003756 stirring Methods 0.000 description 12
- 238000001179 sorption measurement Methods 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 description 7
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 7
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 235000013601 eggs Nutrition 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 235000021317 phosphate Nutrition 0.000 description 6
- 239000011575 calcium Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010088842 Fibrinolysin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- -1 polyethylene- Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000002510 pyrogen Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002196 fr. b Anatomy 0.000 description 2
- 210000003918 fraction a Anatomy 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000003415 peat Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000881711 Acipenser sturio Species 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241000209202 Bromus secalinus Species 0.000 description 1
- 101100533762 Caenorhabditis elegans snf-5 gene Proteins 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 241000237074 Centris Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101100286286 Dictyostelium discoideum ipi gene Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- 241001091433 Itea Species 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241001102832 Meseres Species 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 241001163743 Perlodes Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 241000711981 Sais Species 0.000 description 1
- DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
- 235000013559 Schnittsellerie Nutrition 0.000 description 1
- 244000169997 Schnittsellerie Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000287182 Sturnidae Species 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 101150041626 ipi gene Proteins 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000020046 sherry Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 230000001026 thromboplastic effect Effects 0.000 description 1
- CMQCNTNASCDNGR-UHFFFAOYSA-N toluene;hydrate Chemical compound O.CC1=CC=CC=C1 CMQCNTNASCDNGR-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US404156A US3355361A (en) | 1964-10-15 | 1964-10-15 | Recovery and purification of urokinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1442162A1 true DE1442162A1 (de) | 1969-01-16 |
Family
ID=23598395
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19651442162 Pending DE1442162A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
| DE19651642661 Pending DE1642661A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
| DE19651642660 Pending DE1642660A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
| DE19651642662 Pending DE1642662A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19651642661 Pending DE1642661A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
| DE19651642660 Pending DE1642660A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
| DE19651642662 Pending DE1642662A1 (de) | 1964-10-15 | 1965-10-13 | Verfahren zur Gewinnung von Urokinase |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US3355361A (enExample) |
| JP (3) | JPS5142195B1 (enExample) |
| AT (1) | AT278239B (enExample) |
| CH (1) | CH495384A (enExample) |
| DE (4) | DE1442162A1 (enExample) |
| DK (4) | DK117821B (enExample) |
| GB (1) | GB1068817A (enExample) |
| SE (1) | SE314045B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH467075A (de) * | 1964-07-01 | 1969-01-15 | Pharmexbio S A | Verfahren zur Gewinnung von Urokinase |
| US3477910A (en) * | 1966-10-17 | 1969-11-11 | Century Lab Inc | Method of production of urokinase |
| US3542646A (en) * | 1966-11-22 | 1970-11-24 | Green Cross Corp | Process for fractionally obtaining urokinase and blood coagulation accelerator in human urine |
| US3477913A (en) * | 1967-10-31 | 1969-11-11 | Century Lab Inc | Method of production of urokinase |
| US3544427A (en) * | 1968-04-18 | 1970-12-01 | Century Lab Inc | Method of production of urokinase |
| US3620924A (en) * | 1969-04-01 | 1971-11-16 | Baxter Laboratories Inc | Production of acid-active lactase |
| FR2190412A1 (en) * | 1972-06-30 | 1974-02-01 | Choay Sa | Stable,pyrogen-free urokinase prepns - from human urine |
| BE789189A (fr) * | 1971-09-24 | 1973-03-22 | Choay Sa | Perfectionnements aux procedes de preparation, de depyrogenation et de stabilisation de l'urokinase et compositions obtenues |
| JPS5341485A (en) * | 1976-09-25 | 1978-04-14 | Wakamoto Pharma Co Ltd | Removing method of pyrogenic substance containe in urokinase |
| US4066506A (en) * | 1976-10-08 | 1978-01-03 | The United States Of America As Represented By The Secretary Of Health, Education And Welfare | Method of separating and purifying two active forms of urokinase using affinity chromatography |
| JPS53142592A (en) * | 1977-05-13 | 1978-12-12 | Green Cross Corp:The | Stabilization of urokinase heating |
| JPS53142593A (en) * | 1977-12-12 | 1978-12-12 | Green Cross Corp:The | Stabilization of urokinase by heating |
| JPS54155784U (enExample) * | 1978-04-21 | 1979-10-30 | ||
| USRE32271E (en) * | 1979-11-13 | 1986-10-28 | Isolation of plasminogen activators useful as therapeutic and diagnostic agents | |
| DE3068549D1 (en) * | 1979-11-13 | 1984-08-16 | Syed Shaukat Husain | Plasminogen activators useful as therapeutic and diagnostic agents and their isolation |
| US4558010A (en) * | 1980-04-03 | 1985-12-10 | Abbott Laboratories | Recombinant deoxyribonucleic acid which codes for plasminogen activator and method of making plasminogen activator protein therefrom |
| US4370417A (en) * | 1980-04-03 | 1983-01-25 | Abbott Laboratories | Recombinant deoxyribonucleic acid which codes for plasminogen activator |
| JPS58189122A (ja) * | 1982-04-30 | 1983-11-04 | Kaken Pharmaceut Co Ltd | 高脂血症予防治療剤 |
| DE3439980A1 (de) * | 1984-11-02 | 1986-05-07 | Behringwerke Ag, 3550 Marburg | Verfahren zur reinigung sowie pasteurisierung von urokinase |
| US4920051A (en) * | 1988-02-03 | 1990-04-24 | Damon Biotech, Inc. | Recovery of urokinase compounds |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3281331A (en) * | 1961-11-08 | 1966-10-25 | Astra Ab | Process of isolating and separating proteolytic enzymes |
-
1964
- 1964-10-15 US US404156A patent/US3355361A/en not_active Expired - Lifetime
-
1965
- 1965-10-05 GB GB42311/65A patent/GB1068817A/en not_active Expired
- 1965-10-11 CH CH1400465A patent/CH495384A/de not_active IP Right Cessation
- 1965-10-12 AT AT921765A patent/AT278239B/de not_active IP Right Cessation
- 1965-10-13 DE DE19651442162 patent/DE1442162A1/de active Pending
- 1965-10-13 DE DE19651642661 patent/DE1642661A1/de active Pending
- 1965-10-13 DE DE19651642660 patent/DE1642660A1/de active Pending
- 1965-10-13 DE DE19651642662 patent/DE1642662A1/de active Pending
- 1965-10-14 DK DK527265AA patent/DK117821B/da unknown
- 1965-10-15 SE SE13409/65A patent/SE314045B/xx unknown
- 1965-10-15 JP JP40062990A patent/JPS5142195B1/ja active Pending
-
1967
- 1967-02-13 DK DK77567AA patent/DK115536B/da unknown
- 1967-02-13 DK DK77467AA patent/DK112162B/da unknown
- 1967-02-13 DK DK77667AA patent/DK112232B/da unknown
-
1976
- 1976-05-14 JP JP5521276A patent/JPS5619229B1/ja active Pending
- 1976-05-14 JP JP5521176A patent/JPS5619228B1/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CH495384A (de) | 1970-08-31 |
| DE1642662A1 (de) | 1971-05-19 |
| DK115536B (da) | 1969-10-20 |
| JPS5619229B1 (enExample) | 1981-05-06 |
| DE1642660A1 (de) | 1971-07-29 |
| GB1068817A (en) | 1967-05-17 |
| US3355361A (en) | 1967-11-28 |
| JPS5619228B1 (enExample) | 1981-05-06 |
| SE314045B (enExample) | 1969-09-01 |
| DK117821B (da) | 1970-06-08 |
| JPS5142195B1 (enExample) | 1976-11-13 |
| AT278239B (de) | 1970-01-26 |
| DK112232B (da) | 1968-11-25 |
| DE1642661A1 (de) | 1971-07-29 |
| DK112162B (da) | 1968-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hovig | Release of a platelet-aggregating substance (adenosine diphosphate) from rabbit blood platelets induced by saline “extract” of tendons | |
| DE3027105C2 (enExample) | ||
| Swim et al. | Effect of Pluronic F68 on growth of fibroblasts in suspension on rotary shaker | |
| DE1642662A1 (de) | Verfahren zur Gewinnung von Urokinase | |
| DE69230243T2 (de) | Enzymatische neutralisierung von heparin | |
| Schor et al. | Occurrence of a fetal fibroblast phenotype in familial breast cancer | |
| de Louvois et al. | Inactivation of penicillin by purulent exudates. | |
| DE2619667A1 (de) | Pharmazeutisches mittel | |
| EP0018353B1 (de) | Verfahren zur Herstellung von nebenwirkungsfreien Plasmafraktionen | |
| DE2440529C3 (de) | Hyaluronidase-Präparat aus menschlicher Plazenta | |
| Contrepois et al. | Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans | |
| DE69737500T2 (de) | Gereinigte Multimerase | |
| Blomfield et al. | Hypersecretion of zymogen granules in the pathogenesis of cystic fibrosis | |
| Pope et al. | The preparation of diphtheria antitoxin in a state of high purity | |
| Sarles et al. | Hereditary nephritis, retinitis pigmentosa and chromosomal abnormalities | |
| WO2019025387A1 (de) | Verfahren und zusammensetzung zur stabilisierung zellfreier nukleinsäuren und zellen | |
| DE69727736T2 (de) | Verfahren zur Aktivierung von Prothrombin zu Thrombin | |
| DE3306944A1 (de) | Fibrinolytisch aktives mittel und verfahren zu seiner herstellung | |
| SU1231004A1 (ru) | Способ подготовки сточных вод дл сельскохоз йственного использовани | |
| DE2314478B2 (de) | 3-Substituierte Rifamycin-SV-derivate, Verfahren zu ihrer Herstellung und therapeutische Zubereitung, die diese Verbindungen enthält | |
| Basset et al. | The “calcium-phosphate product” in an in vitro system of surviving bone | |
| Sophasan et al. | Tamm Horsfall mucoprotein in urine of potential bladder stone formers | |
| Rous et al. | OBSERVATIONS ON SOME CAUSES OF GALL STONE FORMATION: II. On Certain Special Nuclei of Deposition in Experimental Cholelithiasis. | |
| Pruzanski et al. | Bacteriolytic and bactericidal activity of sera and synovial fluids in rheumatoid arthritis and in osteoarthritis | |
| EP0281089B1 (de) | Verfahren zur Herstellung von Faktor VIII:C-Mangelplasma und ein so erhaltenes Mangelplasma |